Brought to you by 
Basilea grants Cardiome rights to ceftobiprole in Europe and Israel
28 Sep 2017
Executive Summary
Basilea Pharmaceutica International Ltd. licensed Cardiome Pharma Corp. exclusive rights to distribute its antibiotic Zevtera (ceftobiprole) in more than 30 European countries (excluding Nordic countries) and Israel.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Basilea grants Cardiome rights to ceftobiprole in Europe and Israel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice